Untreated diabetes mellitus, but not impaired fasting glucose, is associated with increased left ventricular mass and concentric hypertrophy in an elderly, healthy, Swedish population

IJC Metabolic and Endocrine

Volumn 9, Issue , 2015, Pages 39-47

  Pareek, Manan ^a   Aharaz, Abdellatif ^a   Nielsen, Mette Lundgren ^a   Gerke, Oke ^a   Leósdóttir, Margrét ^b   Møller, Jacob Eifer ^a   Andersen, Niels Holmark ^c   Nilsson, Peter M ^d   Olsen, Michael Hecht ^a,e  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d LUND UNIVERSITY   (Sweden)

^e NORTH WEST UNIVERSITY   (South Africa)

Author keywords

Concentric; Diabetes mellitus; Diastolic dysfunction; Fasting plasma glucose; Left ventricular hypertrophy; Left ventricular mass index

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHEMILUMINESCENCE IMMUNOASSAY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; MALE; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; RISK FACTOR;

EID: 84949204942     PISSN: 22147624     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcme.2015.10.005     Document Type: Article

References (50)

1. Ghali J.K., Liao Y., Simmons B., Castaner A., Cao G., Cooper R.S. The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease. Ann. Intern. Med. 1992, 117(10):831-836.
2. Haider A.W., Larson M.G., Benjamin E.J., Levy D. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J. Am. Coll. Cardiol. 1998, 32(5):1454-1459.
3. Cioffi G., Rossi A., Zoppini G., Targher G., de Simone G., Devereux R.B., et al. Inappropriate left ventricular mass independently predicts cardiovascular mortality in patients with type 2 diabetes. Int. J. Cardiol. 2013, 168(5):4953-4956.
4. Levy D., Garrison R.J., Savage D.D., Kannel W.B., Castelli W.P. Prognostic implications of echocardiographically determined left ventricular mass in the framingham heart study. N. Engl. J. Med. 1990, 322(22):1561-1566.
5. Bluemke D.A., Kronmal R.A., Lima J.A., Liu K., Olson J., Burke G.L., et al. The relationship of left ventricular mass and geometry to incident cardiovascular events: the MESA (multi-ethnic study of atherosclerosis) study. J. Am. Coll. Cardiol. 2008, 52(25):2148-2155.
6. Eguchi K., Ishikawa J., Hoshide S., Ishikawa S., Pickering T.G., Schwartz J.E., et al. Differential impact of left ventricular mass and relative wall thickness on cardiovascular prognosis in diabetic and nondiabetic hypertensive subjects. Am. Heart J. 2007, 154(1):79 e9-79 15.
7. Gerdts E., Cramariuc D., de Simone G., Wachtell K., Dahlof B., Devereux R.B. Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE study). Eur. J. Echocardiogr. 2008, 9(6):809-815.
8. Marcus R., Krause L., Weder A.B., Dominguez-Meja A., Schork N.J., Julius S. Sex-specific determinants of increased left ventricular mass in the tecumseh blood pressure study. Circulation 1994, 90(2):928-936.
9. Gardin J.M., Wagenknecht L.E., Anton-Culver H., Flack J., Gidding S., Kurosaki T., et al. Relationship of cardiovascular risk factors to echocardiographic left ventricular mass in healthy young black and white adult men and women. The CARDIA study. Coronary artery risk development in young adults. Circulation 1995, 92(3):380-387.
10. Gardin J.M., Brunner D., Schreiner P.J., Xie X., Reid C.L., Ruth K., et al. Demographics and correlates of five-year change in echocardiographic left ventricular mass in young black and white adult men and women: the coronary artery risk development in young adults (CARDIA) study. J. Am. Coll. Cardiol. 2002, 40(3):529-535.
11. de Simone G., Palmieri V., Bella J.N., Celentano A., Hong Y., Oberman A., et al. Association of left ventricular hypertrophy with metabolic risk factors: the HyperGEN study. J. Hypertens. 2002, 20(2):323-331.
12. Lorber R., Gidding S.S., Daviglus M.L., Colangelo L.A., Liu K., Gardin J.M. Influence of systolic blood pressure and body mass index on left ventricular structure in healthy African-American and white young adults: the CARDIA study. J. Am. Coll. Cardiol. 2003, 41(6):955-960.
13. Heckbert S.R., Post W., Pearson G.D., Arnett D.K., Gomes A.S., Jerosch-Herold M., et al. Traditional cardiovascular risk factors in relation to left ventricular mass, volume, and systolic function by cardiac magnetic resonance imaging: the multiethnic study of atherosclerosis. J. Am. Coll. Cardiol. 2006, 48(11):2285-2292.
14. Lee M., Gardin J.M., Lynch J.C., Smith V.E., Tracy R.P., Savage P.J., et al. Diabetes mellitus and echocardiographic left ventricular function in free-living elderly men and women: the cardiovascular health study. Am. Heart J. 1997, 133(1):36-43.
15. Devereux R.B., Roman M.J., Paranicas M., O'Grady M.J., Lee E.T., Welty T.K., et al. Impact of diabetes on cardiac structure and function: the strong heart study. Circulation 2000, 101(19):2271-2276.
16. Palmieri V., Bella J.N., Arnett D.K., Liu J.E., Oberman A., Schuck M.Y., et al. Effect of type 2 diabetes mellitus on left ventricular geometry and systolic function in hypertensive subjects: hypertension genetic epidemiology network (HyperGEN) study. Circulation 2001, 103(1):102-107.
17. Eguchi K., Boden-Albala B., Jin Z., Rundek T., Sacco R.L., Homma S., et al. Association between diabetes mellitus and left ventricular hypertrophy in a multiethnic population. Am. J. Cardiol. 2008, 101(12):1787-1791.
18. Rutter M.K., Parise H., Benjamin E.J., Levy D., Larson M.G., Meigs J.B., et al. Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the framingham heart study. Circulation 2003, 107(3):448-454.
19. De Marco M., de Simone G., Roman M.J., Chinali M., Lee E.T., Calhoun D., et al. Cardiac geometry and function in diabetic or prediabetic adolescents and young adults: the strong heart study. Diabetes Care 2011, 34(10):2300-2305.
20. Ilercil A., Devereux R.B., Roman M.J., Paranicas M., O'Grady M.J., Welty T.K., et al. Relationship of impaired glucose tolerance to left ventricular structure and function: the strong heart study. Am. Heart J. 2001, 141(6):992-998.
21. Berglund G., Nilsson P., Eriksson K.F., Nilsson J.A., Hedblad B., Kristenson H., et al. Long-term outcome of the malmo preventive project: mortality and cardiovascular morbidity. J. Intern. Med. 2000, 247(1):19-29.
22. World Health Organization Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia. Report of a WHO/IDF consultation 2006, ([cited 2015 3 Apr]. Available from: http://www.who.int/diabetes/publications/diagnosis_diabetes2006/en/).
23. Lang R.M., Badano L.P., Mor-Avi V., Afilalo J., Armstrong A., Ernande L., et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the european association of cardiovascular imaging. J. Am. Soc. Echocardiogr. 2015, 28(1):1-39. (e14).
24. Leosdottir M., Willenheimer R., Plehn J., Borgquist R., Gudmundsson P., Harris T.B., et al. Myocardial structure and function by echocardiography in relation to glucometabolic status in elderly subjects from 2 population-based cohorts: a cross-sectional study. Am. Heart J. 2010, 159(3):414-420. (e4).
25. Nagueh S.F., Appleton C.P., Gillebert T.C., Marino P.N., Oh J.K., Smiseth O.A., et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J. Am. Soc. Echocardiogr. 2009, 22(2):107-133.
26. Pareek M., Nielsen M.L., Gerke O., Leosdottir M., Moller J.E., Hindersson P., et al. Worsening diastolic function is associated with elevated fasting plasma glucose and increased left ventricular mass in a supra-additive fashion in an elderly, healthy, Swedish population. Int. J. Cardiol. 2015, 184:466-472.
27. Savage D.D., Garrison R.J., Kannel W.B., Levy D., Anderson S.J., Stokes J., et al. The spectrum of left ventricular hypertrophy in a general population sample: the framingham study. Circulation 1987, 75(1 Pt 2):I26-I33.
28. Levy D., Anderson K.M., Savage D.D., Kannel W.B., Christiansen J.C., Castelli W.P. Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The framingham heart study. Ann. Intern. Med. 1988, 108(1):7-13.
29. Dawson A., Morris A.D., Struthers A.D. The epidemiology of left ventricular hypertrophy in type 2 diabetes mellitus. Diabetologia 2005, 48(10):1971-1979.
30. Kiencke S., Handschin R., von Dahlen R., Muser J., Brunner-Larocca H.P., Schumann J., et al. Pre-clinical diabetic cardiomyopathy: prevalence, screening, and outcome. Eur. J. Heart Fail. 2010, 12(9):951-957.
31. Rivera Otero J.M., Talens-Visconti R., Salvador A., Bertomeu V., Miro V., Jordan A., et al. Ventricular hypertrophy increases NT-proBNP in subjects with and without hypertension. Int. J. Cardiol. 2004, 96(2):265-271.
32. Capaldo B., Di Bonito P., Iaccarino M., Roman M.J., Lee E.T., Devereux R.B., et al. Cardiovascular characteristics in subjects with increasing levels of abnormal glucose regulation: the strong heart study. Diabetes Care 2013, 36(4):992-997.
33. Rerkpattanapipat P., D'Agostino R.B., Link K.M., Shahar E., Lima J.A., Bluemke D.A., et al. Location of arterial stiffening differs in those with impaired fasting glucose versus diabetes: implications for left ventricular hypertrophy from the multi-ethnic study of atherosclerosis. Diabetes 2009, 58(4):946-953.
34. Unwin N., Shaw J., Zimmet P., Alberti K.G. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet. Med. 2002, 19(9):708-723.
35. Dzau V.J., Antman E.M., Black H.R., Hayes D.L., Manson J.E., Plutzky J., et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation 2006, 114(25):2850-2870.
36. Dzau V.J., Antman E.M., Black H.R., Hayes D.L., Manson J.E., Plutzky J., et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part II: clinical trial evidence (acute coronary syndromes through renal disease) and future directions. Circulation 2006, 114(25):2871-2891.
37. O'Rourke M.F., Safar M.E., Dzau V. The cardiovascular continuum extended: aging effects on the aorta and microvasculature. Vasc. Med. 2010, 15(6):461-468.
38. Wang T.J., Larson M.G., Levy D., Benjamin E.J., Leip E.P., Wilson P.W., et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004, 109(5):594-600.
39. Wang T.J., Larson M.G., Keyes M.J., Levy D., Benjamin E.J., Vasan R.S. Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals. Circulation 2007, 115(11):1345-1353.
40. Nishikimi T., Yoshihara F., Morimoto A., Ishikawa K., Ishimitsu T., Saito Y., et al. Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. Hypertension 1996, 28(1):22-30.
41. Tschope C., Kasner M., Westermann D., Gaub R., Poller W.C., Schultheiss H.P. The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. Eur. Heart J. 2005, 26(21):2277-2284.
42. Lukowicz T.V., Fischer M., Hense H.W., Doring A., Stritzke J., Riegger G., et al. BNP as a marker of diastolic dysfunction in the general population: importance of left ventricular hypertrophy. Eur. J. Heart Fail. 2005, 7(4):525-531.
43. Suzuki M., Yamamoto K., Watanabe S., Iwata T., Hamada M., Hiwada K. Association between elevated brain natriuretic peptide levels and the development of left ventricular hypertrophy in patients with hypertension. Am. J. Med. 2000, 108(8):627-633.
44. Schafer S., Kelm M., Mingers S., Strauer B.E. Left ventricular remodeling impairs coronary flow reserve in hypertensive patients. J. Hypertens. 2002, 20(7):1431-1437.
45. Galderisi M. Diastolic dysfunction and diabetic cardiomyopathy: evaluation by Doppler echocardiography. J. Am. Coll. Cardiol. 2006, 48(8):1548-1551.
46. Gerdts E., Okin P.M., Omvik P., Wachtell K., Dahlof B., Hildebrandt P., et al. Impact of diabetes on treatment-induced changes in left ventricular structure and function in hypertensive patients with left ventricular hypertrophy. The LIFE study. Nutr. Metab. Cardiovasc. Dis. 2009, 19(5):306-312.
47. Okin P.M., Devereux R.B., Gerdts E., Snapinn S.M., Harris K.E., Jern S., et al. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the losartan intervention for endpoint (LIFE) reduction in hypertension study. Circulation 2006, 113(12):1588-1596.
48. Liu J., Masurekar M.R., Vatner D.E., Jyothirmayi G.N., Regan T.J., Vatner S.F., et al. Glycation end-product cross-link breaker reduces collagen and improves cardiac function in aging diabetic heart. Am. J. Physiol. Heart Circ. Physiol. 2003, 285(6):H2587-H2591.
49. World Health Organization Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus. Abbreviated report of a WHO consultation 2011, ([cited 2015 Apr 3]. Available from: http://www.who.int/diabetes/publications/diagnosis_diabetes2011/en/).
50. Diaz T., Pencina M.J., Benjamin E.J., Aragam J., Fuller D.L., Pencina K.M., et al. Prevalence, clinical correlates, and prognosis of discrete upper septal thickening on echocardiography: the framingham heart study. Echocardiography 2009, 26(3):247-253.